ORTX Orchard Therapeutics plc

17.79
-0.72  -4%
Previous Close 18.51
Open 18.5
Price To Book 4.9
Market Cap 1527556140
Shares 85,866,000
Volume 130,255
Short Ratio
Av. Daily Volume 112,997

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented February 24, 2019.
OTL-102
X-linked chronic granulomatous disease (X-CGD)
Phase 1/2 engraftment data due 2019.
OTL-101
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Phase 1/2 data to be presented April 29, 2019, 10:30am.
OTL-300
Transfusion-dependent beta-thalassemia (TDBT)
Phase 2 full data released March 27, 2019.
OTL-200
Metachromatic leukodystrophy (MLD)

Latest News

  1. Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting
  2. Will Orchard Therapeutics Continue to Surge Higher?
  3. Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
  4. Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
  5. Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer
  6. What Kind Of Shareholders Own Orchard Therapeutics plc (NASDAQ:ORTX)?
  7. Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019
  8. Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
  9. Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019
  10. Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD
  11. Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID
  12. Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
  13. Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine
  14. Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy
  15. Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
  16. 2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma
  17. Positive Data From Orchard Therapeutics Turns Goldman Sachs Bullish
  18. Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
  19. Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California